Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin and Empagliflozin in Preclinical Alzheimer's Disease and Mild Cognitive Impairment
NCT05081219Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Generex Oral-lyn, empagliflozin in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Wake Forest University Health Sciences. Started Sep 2021; status: completed.
02
Drugs
Generex Oral-lynempagliflozin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05081219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081219.